MetaCap

Helus Pharma (HELP) vs Rezolute (RZLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Helus Pharma (HELP) has outperformed Rezolute (RZLT) over the past year, gaining 9.3% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -88.1% for HELP. Helus Pharma is the larger company by market cap ($487.7 million vs $465.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HELP+9.30%RZLT-60.12%
+163%+33%-98%
Nov 21, 20251 yearNov 20, 2026
HELP-90.14%RZLT-32.41%
+94%-4%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HELP versus RZLT key metrics
MetricHELPRZLT
Share price$6.11$3.92
Market cap$487.68M$465.58M
1-day change-9.88%-6.67%
YTD return-25.31%+66.10%
1-year return+9.30%-60.12%
5-year return-88.09%-26.87%
EPS (TTM)$-4.25$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-77.60M
52-week high$15.15$11.17
52-week low$3.76$1.07
Distance from 52-week high-59.67%-64.89%
Analyst consensusnonestrong_buy
Avg. price target upside+564.81%+175.51%
Average volume1.83M1.66M
Shares outstanding79.81M118.77M
Employees10063
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HELP has outperformed RZLT by 69.4 percentage points over the past year.

About Helus Pharma

HELP stock →

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Rezolute

RZLT stock →

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

HELP vs RZLT FAQ

Which is bigger, Helus Pharma or Rezolute?

Helus Pharma (HELP) is larger, with a market capitalization of $487.68M compared with $465.58M for Rezolute (RZLT).

Which stock has performed better over the past year, HELP or RZLT?

HELP returned +9.30% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.

Are Helus Pharma and Rezolute in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons